Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Irbesartan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Irbesartan. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-004205-89 Sponsor Protocol Number: CTSUHARP3 Start Date*: 2014-09-15
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (HARP)-III
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10038443 Renal failure and impairment HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004809-58 Sponsor Protocol Number: HEBRO-001 Start Date*: 2019-04-04
    Sponsor Name:Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N)
    Full Title: Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEBRO Study)
    Medical condition: Primary Hypertension and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000614-12 Sponsor Protocol Number: CV131-186 Start Date*: 2005-11-28
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome. Irbesartan en el tratamiento del paciente hipertenso con síndrome metabólico
    Medical condition: Hypertension, nos
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000020-32 Sponsor Protocol Number: CV131-176 Start Date*: 2005-02-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension
    Medical condition: Severe Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001176-12 Sponsor Protocol Number: CSPP100A2325 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular ri...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004605-41 Sponsor Protocol Number: 021IGAN17001 Start Date*: 2018-10-04
    Sponsor Name:Retrophin, Inc.
    Full Title: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
    Medical condition: Immunoglobulin A Nephropathy (IgAN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001267-11 Sponsor Protocol Number: Jens05 Start Date*: 2008-09-29
    Sponsor Name:Department of Nephrology
    Full Title: Saving residual kidney function among haemodialysis patients receiving irbesartan - a double blind randomised study
    Medical condition: We want to investigate if an angiotensin II antagonist (irbesartan) has beneficial effects regarding residual kidney function and heart/vessels among haemodialysis patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049415 Renin-angiotensin system inhibition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002809-23 Sponsor Protocol Number: CV131-235 Start Date*: 2005-11-18
    Sponsor Name:Bristol-Myers Squibb SL
    Full Title: Electrophysiological effects of Irbesartan in patients with paroxysmal AF Efectos electrofisiológicos del Irbesartán en sujetos con FA paroxística
    Medical condition: Patients with paroxysmal atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019302-16 Sponsor Protocol Number: 2010GU001B Start Date*: 2010-09-13
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome
    Medical condition: Marfan Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001100-38 Sponsor Protocol Number: FARM97AJNN Start Date*: 2014-07-09
    Sponsor Name:DIPART. DI NEUROSCIENZE, SCIENZE RIPRODUTTIVE E ODONTOSTOMATOLOGICHE DELL’UNIVERSITà DEGLI STUDI DI NAPOLI “FEDERICO II"
    Full Title: Antagonists of Angiotensin II Receptors in sepsis
    Medical condition: SEPSIS
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004993-26 Sponsor Protocol Number: CSPP100A2351 Start Date*: 2006-05-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg, compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.1 10020772
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) IT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000362-39 Sponsor Protocol Number: CSPP100A2243 Start Date*: 2005-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an a...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023104-28 Sponsor Protocol Number: MEIN/10/Neb+HCTZ-Hyp/001 Start Date*: 2011-10-20
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly pa...
    Medical condition: Isolated Systolic Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10050591 Isolated systolic hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001610-38 Sponsor Protocol Number: JAGG2020-1 Start Date*: 2020-09-16
    Sponsor Name:Slagelse Sygehus
    Full Title: Irbesartan and Oseltamivir treatment of COVID-19 infection.
    Medical condition: The combined treatment in this trial will be used to treat patients with Covid-19 infection in order to prevent the patients need for further treatment in a hospital.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002161-36 Sponsor Protocol Number: PM-C-0024 Start Date*: 2006-02-08
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: Randomized comparison of a two-month regimen of irbesartan versus enalapril on cardiovascular markers in patients with acute coronary syndrome without ST segment elevation.
    Medical condition: Acute coronary syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023612-14 Sponsor Protocol Number: N/A Start Date*: 2013-03-08
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso...
    Medical condition: Marfan syndrome.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10026829 Marfan's syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000501-29 Sponsor Protocol Number: CRC-ER-1_2007 Start Date*: 2008-10-27
    Sponsor Name:University Hospital of Erlangen
    Full Title: Low grade albuminuria: reaching a new target for irbesartan
    Medical condition: low grade albuminuria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001580 Albuminuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002358-38 Sponsor Protocol Number: RET-D-001 Start Date*: 2015-04-28
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED...
    Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005141-23 Sponsor Protocol Number: 021FSGS16010 Start Date*: 2018-09-18
    Sponsor Name:Retrophin, Inc.
    Full Title: A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with...
    Medical condition: Focal segmental glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Prematurely Ended) DK (Trial now transitioned) EE (Trial now transitioned) SE (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012993-10 Sponsor Protocol Number: MEN/09/ZOF-IPE/001 Start Date*: 2009-09-24
    Sponsor Name:A. MENARINI I.F.R.
    Full Title: EFFICACY AND SAFETY OF ZOFENOPRIL+HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN+HYDROCHLOROTHIAZIDE COMBINATION IN METABOLIC SYNDROME PATIENTS WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOU...
    Medical condition: PATIENTS affected by METABOLIC SYNDROME WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS MONOTHERAPY
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052066 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:43:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA